Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates
Christine A Blauvelt(University of California, San Francisco), Stephanie L. Gaw(University of California, San Francisco), Mary Prahl(University of California, San Francisco), Michelle E. Roh(University of California, San Francisco), Aishwarya Natarajan(University of California, San Francisco), Valerie J. Flaherman(University of California, San Francisco), Molly Zeme(University of California, San Francisco), Nadia Bourdoud(University of California, San Francisco), Adrienne Epstein(Boston University)
Cited by 30
Related Papers
Update: Interim Guidance for the Diagnosis, Evaluation, and Management of Infants with Possible Congenital Zika Virus Infection — United States, October 2017
|MMWR Morbidity and Mortality Weekly Report|2017|218
Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity
|Science Translational Medicine|2022|139
Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy
|NEJM Evidence|2022|130
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
|Science Translational Medicine|2022|125